Identification of potential diagnostic biomarkers in MMPs for pancreatic carcinoma

Junhao Xie, PhD\textsuperscript{a}, Xianzhu Zhou, MD\textsuperscript{a,b}, Rui Wang, PhD\textsuperscript{b}, Jiulong Zhao, PhD\textsuperscript{a}, Jian Tang, PhD\textsuperscript{a}, Qichen Zhang, PhD\textsuperscript{a}, Yiqi Du, PhD\textsuperscript{a,c}, Yanan Pang, PhD\textsuperscript{a,c,*}

Abstract
Pancreatic cancer (PC) is a malignant tumor which ranks fourth in cancer-related death. However, the specificity and sensitivity of traditional biomarkers such as carbohydrate antigen 19-9 no longer meet the clinical requirements. Tools as ONCOMINE and Gene Expression Profiling Interactive Analysis (GEPIA) were used to analyze the differential expression of matrix metalloproteinases (MMPs) in PC and adjacent tissues. For further analysis, we adopted database for annotation, visualization and integrated discovery (DAVID 6.8), transcriptional regulatory relationships unraveled by sentence-based text (TRRUST) and other tools. We also identified drugs targeted the selected MMPs.

Eight MMPs (MMP1, MMP2, MMP7, MMP9, MMP11, MMP12, MMP14, and MMP28) were differentially expressed in PC and adjacent tissue. MMP1 \( (P = .0189)\), MMP7 \( (P = .000216)\), MMP11 \( (P = .0209)\), MMP14 \( (P = .00611)\) were correlated with the pathological stages of PC. Patients with higher expression of MMP1 \( (P = .0011)\), MMP2 \( (P = .011)\), MMP7 \( (P = .0081)\), MMP9 \( (P = .046)\), MMP11 \( (P = .0019)\), MMP12 \( (P = .0011)\), MMP14 \( (P = .0011)\), and MMP28 \( (P = 6.3e-06)\) showed poor prognosis. Ten transcription factors were associated with the up-regulation of selected MMPs. Marimastat (DB00786) was found to target selected MMPs.

Our research revealed that selected MMPs played an important role in the early diagnosis and prognosis of PC.

Abbreviations: CA19-9 = carbohydrate antigen 19-9, cBioPortal = the cBio cancer genomics portal, DAVID = Database for Annotation, Visualization and Integrated Discovery, DB = DrugBank, DFS = disease free survival, ECM = extracellular matrix, ETS2 = ETS proto-oncogene 2, ETV4 = ETS variant transcription factor 4, FOS = Fos proto-oncogene, GEPIA = Gene Expression Profiling Interactive Analysis, JUN = Jun proto-oncogene, MAZ = MYC associated zinc finger protein, MF = Molecular function, MMPs = Matrix metalloproteinases, PC = pancreatic cancer, PPI = protein–protein interaction, RELA = RELA proto-oncogene, SP1 = Sp1 transcription factor, SRF = serum response factor, STAT3 = signal transducer and activator of transcription 3, TCGA = The Cancer Genome Atlas, TRRUST = transcriptional regulatory relationships unraveled by sentence-based text.

Keywords: biomarker, diagnosis, MMPs, pancreatic carcinoma

1. Introduction
Pancreatic carcinoma (PC) is a malignant tumor which ranks fourth in cancer-related death.\cite{11} It accounts for over 220,000 new cases and over 200,000 deaths worldwide each year and its incidence and mortality continue to increase.\cite{12,13} There are several types of PC, 90% of which are pancreatic ductal adenocarcinoma.\cite{6,7} Due to its extremely aggressive behavior and rapid progression, the 5-year survival rate of PC patients is less than 9%.\cite{8} The only curable treatment for PC patients may be surgical resection.\cite{9,10} However, most PC patients were diagnosed at unresectable stage and the effective screening methods are lacking.\cite{11}

By searching useful biomarkers, early diagnosis is useful for improving the prognosis of PC patients.\cite{12,14} Carbohydrate antigen 19-9 (CA19-9) is one biomarker mainly expressed in PC tissues with low specificity and sensitivity.\cite{11,15} Previous studies had also identified several biomarkers which were useful in the diagnosis of PC.\cite{16} Unfortunately, they have the same drawbacks with CA19-9.\cite{17} Consequently, it is urgent to identify new biomarkers used for the early diagnosis of PC. The matrix metalloproteinases (MMPs) family consists 25 members, and most of them are expressed in human tissues.\cite{18} Studies indicated that MMPs were essential in embryo formation, neovascularization, and the metastasis of malignant tumor cells including PC.\cite{19} MMPs are involved in the development, progression and
invasion of tumor cells by modulating the cell-extracellular matrix (ECM) adhesion and promoting angiogenesis.\cite{8,9} Hence, MMPs may be the potential biomarkers for PC.

Previous studies had already revealed the universal expression of MMPs in PC tissues. Their function and underlying mechanisms have also been clearly clarified.\cite{10,12} However, further analysis should be performed to identify suitable subtypes of MMPs as diagnostic and prognosis biomarkers for PC. Recently, new high-throughput sequencing technology had developed rapidly and numerous databases had been established. It is possible to perform a comprehensive and integrated analysis for the expression of MMPs in PC.\cite{20,21} We aimed to identify potential diagnostic and prognosis biomarkers in MMPs through comprehensive bioinformatics analysis for the diagnostic of PC based on public databases. The important role of selected MMPs in the progression of PC will also be explored.

2. Materials and methods

2.1. ONCOMINE

ONCOMINE (www.oncomine.org) contains 65 microarray datasets, 4700 microarrays. More than 480 million gene expression data are presented.\cite{22,23} Here, we evaluated the expression of MMPs in PC by using the data in ONCOMINE. A P value <.05, fold change of 2, and gene ranking in the top 10% were set as the significance thresholds in our study. Student t test was used to analyze the expression difference.

2.2. GEPIA (gene expression profiling interactive analysis)

Based on the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression data, GEPIA is one useful tool to analyze the expression and interaction of cancer and normal genes.\cite{24} Pathological stage, prognostic analysis, and the relative expression levels of MMPs in PC and normal tissues were performed with GEPIA. Student t test was used to analyze the expression difference, with a cutoff of 0.05. Besides, the cutoff value of fold change was set as 2. Prognostic analysis was presented using Kaplan–Meier curves and the Kaplan–Meier plotter online tool was also applied.

2.3. cBioPortal (cBio cancer genomics portal)

cBioPortal is one open platform and provide genomic data and clinical information from more than 215 studies for the study of multi-dimensional cancer genome. It enables researchers to access massive amounts of data from large-scale cancer genomics and convert them into visual charts quickly and efficiently.\cite{25} The genetic changes of differentially expressed MMPs were also analyzed by cBioPortal. The co-expression and the network module of MMPs were also explored.

2.4. STRING

Online database STRING provides information on protein-gene interaction pathways, co-expression, co-localization, and protein domain similarity.\cite{26} To explore the interactions between MMPs, STRING was applied to differentially expressed MMPs for protein–protein interaction (PPI) network analysis.

2.5. GeneMANIA

GeneMANIA was applied to search related genes and protein interactions by searching the public biological datasets.\cite{37}

2.6. DAVID 6.8 (database for annotation, visualization and integrated discovery)

To explore the biological significance of differently expressed MMPs in PC, gene ontology, and Kyoto Encyclopedia of Genes and Genome analysis were performed using DAVID 6.8 and top 10 pathways were selected.\cite{28}

2.7. Drugbank (DB)

DB is a bioinformatics and chemical informatics database provided by University of Alberta. It was used to retrieve new drug targets, compare drug structures and study drug mechanisms.\cite{29,30} Relevant matching drugs for differentially expressed MMPs were identified by DB.

2.8. TRRUST (transcriptional regulatory relationships unraveled by sentence-based text)

The transcriptional regulatory network analysis of differentially expressed MMPs was performed using the TRRUST.

2.9. Ethics

This study was approved by the Institutional Animal Care and Use Committee of Changhai Hospital, Second Military Medical University.

3. Results

3.1. Abnormal expression of MMPs in PC patients

The expression levels of 25 MMPs were explored in different cancer types and adjacent tissues using the ONCOMINE database. As shown in Figure 1 and Figure S1, Supplemental Digital Content, http://links.lww.com/MD/G179, the expression levels of MMP1, MMP2, MMP7, MMP9, MMP11, MMP12, MMP14, and MMP28 were significantly upregulated in PC tissues, while MMP24 and MMP25 were significantly down-regulated. Moreover, no changes were found among other MMPs. Detailed information on the abnormal expression of MMPs obtained by ONCOMINE was presented in Table 1. Consistently, Tho et al also found that the expression of MMP1 is associated with the prognosis of human pancreatic ductal adenocarcinoma.\cite{32} Yueguang et al indicated that MMP2 was upregulated in PC tissues, which enhanced the invasion and metastasis of PC cells.\cite{33} Compared with adjacent normal tissues, Lu-Lu Zhai et al also found a significant increase in the expression of MMP2 in PC tissues.\cite{34,35} Besides, MMP7 and MMP11 were also overexpressed in PC tissues compared with chronic pancreatitis.\cite{36} Jones et al also revealed the upregulated expression of MMP7, MMP8, MMP9, and MMP11 in PC tissues.\cite{37}

Additionally, we also examined the relative expression of all MMPs in PC tissues using GEPIA. MMP7 was found to be the highest expressed MMP we evaluated (Fig. 2A). Moreover, the relative expression levels of MMP1, MMP2, MMP7, MMP9, MMP10, MMP11, MMP12, MMP14, MMP19, MMP23A, MMP23B, and MMP28 were found significantly increased in PC tissues compared with adjacent tissues (Fig. 2B). However, the relative expression levels of other MMPs in PC tissues were not significant (Figure S2, Supplemental Digital Content, http://links.lww.com/MD/G180). Combining the results from ONCOMINE and GEPIA, MMP1, MMP2, MMP7, MMP9, MMP11, MMP12, MMP14, and MMP28 were selected as the targets for our further study.
3.2. The prognostic value of selected MMPs in PC patients

We then evaluated the correlation between selected MMPs and the pathological stage of PC patients. We found a significant association between MMP1 ($P = .0189$), MMP7 ($P = .000216$), MMP11 ($P = .0209$), MMP14 ($P = .00611$), and the pathological stages of PC patients (Fig. 3A). Thus, MMP1, MMP7, MMP11, and MMP14 may be the useful prognostic markers for PC patients.

Furthermore, survival analysis indicated that PC patients with highly expressed MMP1 (HR = 2.28 (1.37–3.79), $P = .0011$), MMP2 (HR = 1.96 (1.15–3.34), $P = .011$), MMP7 (HR = 2.02

Table 1. Differential expression of MMP family in pancreatic cancer and adjacent tissue.

| Gene name | Type                  | Fold change | $P$ value | $T$ test | References (PMID) |
|-----------|-----------------------|-------------|-----------|----------|-------------------|
| MMP1      | Pancreatic Ductal Adenocarcinoma | 11.671 | 1.23E-09  | 6.824    | 19260470          |
| MMP2      | Pancreatic Ductal Adenocarcinoma | 5.996 | 3.48E-14  | 9.92     | 19260470          |
| MMP7      | Pancreatic Ductal Adenocarcinoma | 10.743 | 1.21E-12  | 8.69     | 19260470          |
| MMP9      | Pancreatic Adenocarcinoma      | 11.597 | 6.28E-05  | 6.908    | 12750293          |
| MMP11     | Pancreatic Adenocarcinoma      | 15.423 | 3.45E-07  | 10.534   | 12750293          |
| MMP12     | Pancreatic Adenocarcinoma      | 317.536 | 8.19E-08  | 14.368   | 12750293          |
| MMP14     | Pancreatic Carcinoma          | 2.018 | 5.91E-06  | 5.018    | 19732725          |
| MMP24     | Pancreatic Ductal Adenocarcinoma | −1.79 | 0.000485  | −4.801   | 16103885          |
| MMP25     | Pancreatic Ductal Adenocarcinoma | −1.646 | 0.008    | −2.835   | 16103885          |
| MMP28     | Pancreatic Carcinoma          | 4.456 | 3.6E-09   | 7.155    | 19732725          |
Figure 2. (A) Relative expression levels of all MMPs in PC tissues with GEPIA. (B) MMPs expression profile in PC and normal pancreatic tissues from GEPIA database.
MMP1 (HR = 1.65 (1.26–2.72), P = .03), MMP11 (HR = 1.91 (1.26–2.9), P = .0046), MMP12 (HR = 2.02 (1.18–3.44), P = .0011), MMP14 (HR = 2 (1.27–3.16), P = .0011), and MMP28 (HR = 2.6 (1.69–4), P = 6.3e-06) showed poor prognosis (Fig. 3B). We also assessed the correlation between selected MMPs and their clinical outcome by GEPIA. Disease free survival (DFS) curves of all selected MMPs were shown in Supplementary Figure 3A, http://links.lww.com/MD/G181. We found that low expression of both MMP14 (P = .004) and MMP28 (P = 5.2e-05) was significantly associated with longer DFS. The value of selected MMPs in the OS were also evaluated with GEPIA. Results indicated that patients with high expression of MMP1 (P = .03), MMP11 (P = .042), MMP14 (P = .033) and MMP28 (P = 7e-06) showed shorter overall
survival (Figure S3, Supplemental Digital Content, http://links.lww.com/MD/G181). These results suggested that the selected MMPs were involved in the progression of PC.

3.3. Co-expression, genetic alteration, neighbor gene interaction network analysis of selected MMPs in PC patients

We then performed a comprehensive analysis of the molecular characteristics of selected MMPs. Firstly, we evaluated the correlations between selected MMPs by using the GEPIA online tool. The expression of MMP2 was moderately correlated with MMP11 (0.51) and MMP9 with also moderately correlated MMP14 (0.37). The correlation between the expression of MMP2 and MMP14 (0.75), MMP11 and MMP14 (0.75) were highly correlated (Fig. 4A). Furthermore, the correlation among MMP2, MMP9, MMP11, and MMP14 were also presented by scatter plots (Fig. 4B).

The online tool cBioPortal was used for evaluating the genetic alterations of the selected MMPs in queried PC samples. As shown in Figure 5A, MMP1, MMP2, MMP7, MMP9, MMP11, MMP12, MMP14, and MMP28 altered 0.7%, 1.1%, 0.3%, 2%, 0.4%, 0.5%, 1.6% and 1%, respectively. Genetic alterations of selected MMPs in cBioPortal included amplification, deep deletion and mutation (Fig. 5B). These data were obtained from 5 studies including pancreatic adenocarcinoma (ICGC, Nature 2012), pancreatic adenocarcinoma (TCGA, Firehose Legacy), pancreatic cancer (ICGC, Nat Commun 2015), pancreatic adenocarcinoma (QCMG, Nature 2016) and pancreatic adenocarcinoma (TCGA, PanCancer Atlas). Meanwhile, we also conducted a protein–protein interaction (PPI) network analysis of selected MMPs with STRING to explore their potential interaction. As illustrated in Figure 5C, we obtained 18 nodes and 166 edges in the PPI network. There were also 10 other interactors which interacted with selected MMPs. The function of these interactors were associated with cell migration, inflammation, oncogenesis, metastasis, tumorigenesis and progression\(^{38}\) pro-inflammatory, angiogenesis\(^{38-40}\) tissue inhibitors of matrix metalloproteinases, aggressive phenotype of pancreatic carcinoma,\(^{35,41}\) the distant metastasis, and aggressive malignant behaviors of pancreatic cancer.\(^{42}\) Moreover, results of GeneMANIA also indicated that selected MMPs were strongly associated with each other, mainly related to oxidative stress, proteoglycan, lysosomal glycosidase and promotion of cell adhesion and spreading (Fig. 5D).

3.4. Potential transcription factors of selected MMPs

MMP1, MMP2, MMP7, MMP9, MMP11, MMP12, MMP14, and MMP28 were significantly up-regulated in PC tissues compared with adjacent tissues. Thus, we explored the potential transcription factors regulating the differentially expressed MMPs in PC patients by TRRUST. Totally, we found 10 transcription factors, including ETS variant transcription factor 4 (ETV4), signal transducer and activator of transcription 3 (STAT3), Jun proto-oncogene (JUN), MYC associated zinc finger protein (MAZ), RELA proto-oncogene (RELA), serum response factor (SRF), ETS proto-oncogene 2 (ETS2), Sp1 transcription factor (SP1), Fos proto-oncogene (FOS) and Nuclear factor-κB (NF-κB), were associated with the up-regulated of selected MMPs (Table 2). ETV4 was the key transcription factor of MMP1, MMP2, MMP7, and MMP14 (\(P=9.66E-11, \text{FDR}=1.84E-09\)). STAT3 was the key transcription factor of MMP1, MMP2, MMP7, MMP9, and MMP14 (\(P=1.23E-09, \text{FDR}=9.97E-09\)). JUN was the key transcription factor of MMP1, MMP2, MMP9, MMP12, and MMP14 (\(P=1.57E-09, \text{FDR}=9.97E-09\)). MAZ was the key transcription factor of MMP1, MMP9, and MMP14 (\(P=2.80E-09, \text{FDR}=1.33E-08\)). RELA was the key transcription factor of MMP1, MMP2, MMP9, MMP12, and MMP14 (\(P=5.37E-08, \text{FDR}=2.04E-07\)). SRF was the key transcription factor of
MMP2, MMP9, and MMP14 ($P = 1.15E-07$, FDR = 3.63E-07). ETS2 was the key transcription factor of MMP1, MMP2, and MMP9 ($P = 2.47E-07$, FDR = 6.69E-07). SP1 was the key transcription factor of MMP2, MMP9, MMP11, MMP14, and MMP28 ($P = 5.04E-07$, FDR = 1.20E-06). FOS was the key transcription factor of MMP1, MMP7, and MMP9 ($P = 1.45E-06$, FDR = 3.06E-06). NF-κB was the key transcription factor of MMP1, MMP2, and MMP14 ($P = 4.33E-06$, FDR = 7.60E-06). ETV4 was up-regulated in CIC-deficient hepatocellular carcinoma cells, which induces the expression of MMP1\cite{43} and STAT3 was associated with proliferation, growth, and invasion of pancreatic cancer.\cite{44,45} MAZ was significantly upregulated in PC tissues ($P < .0001$) and significantly correlated with certain clinical characteristics of PC patients, such as age, tumor diameter, tumor number, serum CA19-9 level ($P < .05$) and survival time ($P = .0365$).\cite{46} RelA/p65 is found to be activated in most of PC cell lines.\cite{47} Elk-1/TF pathway is a cancer-associated pathway.\cite{48} ETS2 is associated with carcinoma

Figure 5. (A) Genetic alterations of the selected MMPs in the queried PC samples by the online tool cBioPortal. (B) Analyses of genetic variations of MMP family member. (C) Protein–protein interaction (PPI) network analysis of selected MMPs. (D) PPI network and functional analysis from GENEMANIA.
progression and also plays a role in the progression of pancreatic adenocarcinoma, mainly in advanced stages.\[^{49}\] SP1 is known as a key regulator in the carcinogenesis of pancreatic carcinoma.\[^{50}\] FOS is a proto-oncogene in some types of tumors.\[^{51}\] NF-kB, which helps to suppress anti-tumor immune responses, might increase anti-tumor immunity.\[^{52}\]

### 3.5. Functional enrichment analysis of selected MMPs in PC patients

We used DAVID 6.8 and metascape to perform functional enrichment analysis. Ten most enriched gene ontology items in the biological process, molecular function (MF), and cellular component (CC) categories were shown in Tables S1–S3, Supplemental Digital Content, http://links.lww.com/MD/G182, http://links.lww.com/MD/G183, http://links.lww.com/MD/G184, respectively. In the biological process category, extracellular matrix organization (FDR = 2.44E-44), extracellular matrix disassembly (FDR = 1.03E-31), collagen metabolic process (FDR = 3.84E-18), regulation of cell motility (FDR = 6.16E-17), and regulation of cell migration (FDR = 1.76E-16) were considered to be associated with the progression of PC. And cell adhesion molecule binding (FDR = 7.81E-10) may be directly related to the metastasis of PC in the MF category. In contrast, most of the items in the CC category were related to extracellular or secretory components such as extracellular matrix (FDR = 6.05E-25) and secretory granule (FDR = 9.26E-19). These results suggest that selected MMPs were involved in the tumorigenesis of PC.

Moreover, Kyoto Encyclopedia of Genes and Genome pathway analysis was also performed. As illustrated in Table S4, Supplemental Digital Content, http://links.lww.com/MD/G185, proteoglycans in cancer (FDR = 3.35E-18), bladder cancer (FDR = 9.33E-11), Rap1 signaling pathway (FDR = 1.24E-09), ECM-receptor interaction (FDR = 6.67E-09), HIF-1 signaling pathway (FDR = 3.97E-07), PI3K-Akt signaling pathway (FDR = 1.24E-06), and focal adhesion (FDR = 1.95E-06) were the most enriched pathways, which are also commonly associated with tumorigenesis of PC. Lozzi et al found Epac1, a Rap1-specific exchange factor, is highly expressed in pancreatic tumor cells and tissue, and that activation of the Epac1/Rap1 pathway is related to the growth control in pancreatic cancer cell lines.\[^{53}\] Zhang et al reported that Rap1 activity is a key factor in determining the aggressiveness of tumor cells.\[^{54}\] Wang et al revealed the overrepresented ECM-receptor interaction in pancreatic ductal adenocarcinoma.\[^{55}\] Konstantinos Parperis et al revealed that pancreatic carcinoma may be accompanied by paraneoplastic arthritides such as rheumatoid arthritis.\[^{56}\] PI3K-Akt signaling pathway is related to the proliferation, invasion, metastasis and apoptosis of PC.\[^{57,58}\] Focal adhesion kinase expression was significantly correlated with tumor size in PC (P = .004).\[^{59}\]

### 3.6. Seeking potential drugs for selected MMPs Using DB

In the development of many diseases, drugs interacted directly or indirectly with pathogenic biomolecules to achieve therapeutic goals.\[^{60}\] Pathogenic biomolecules belonging to the same family could be inhibited by the same drug.\[^{60}\] Thus, we first queried DB with the selected MMPs and found 5 drugs (DB00786, DB07556, DB07926, DB08403, DB 08482, and DB08491) directly targeting MMP1 (Table 3). For MMP2, there were 6 drugs (DB00786, DB01630, DB04866, DB05387, DB06423, and DB01197) targeting; MMP7 had 4 drugs (DB00786, DB08170, DB08489, and DB08493) targeting; MMP11 had 2 drugs (DB04318 and DB00786) targeting; MMP9 had 10 drugs (DB00786, DB01017, DB01296, DB01949, DB03683, DB05387, DB05495, DB06423, DB01197, and DB07117) targeting; and MMP12 had 10 drugs (DB02118, DB00551, DB03367, DB03880, DB04405, DB05387, DB06423, DB07026, DB07446, and DB07556) targeting (Table 3). However, there was only 1 drug for MMP14 (DB00786) and 1 for MMP28 (DB00786), respectively.

Among drugs we found to target the selected MMPs, DB00786 (Marimastat) was found to target all the MMPs differentially expressed in PC. We also queried DB with marimastat and found marimastat was categorized as amines, hydroxy Acids, metalloendopeptidases, antagonists, inhibitors, and hydroxylamines. Moreover, using the group status of marimastat as an investigational drug, query of DB indicated that it is a drug widely used for the treatment of various cancers. Such as orthotopic oral squamous cell carcinoma,\[^{61}\] gastric carcinoma,\[^{62,63}\] small-cell lung cancer,\[^{64}\] glioma.\[^{65}\] As one matrix-metalloproteinase inhibitor, marimastat is an anti-angiogenic anti-antitumor chemotherapeutic drug.\[^{66}\] Long-term oral administration of marimastat is feasible and safe and is expected to be a first-line therapy for patients with unresectable PC.\[^{67,68}\]

### 4. Discussion

MMPs are a family of zinc-dependent endopeptidases which play crucial role in many physiological processes including tissue remodeling, degradation of various proteins, cell proliferation,
| Symbol | Query_MMPs (8) | Matched_drugs | Name | Group |
|--------|----------------|----------------|------|-------|
| MMP1   | P03956         | DB00786        | Marimastat | investigational, experimental |
|        |                | DB07556        | CSS-27023 | experimental |
|        |                | DB07926        | N-[2-(N-HYDROXYCARBOXYAMIDO)-2-(2-METHYLPROPYL)-PROPAIYL]-O-TYROSINE-N-METHYLAMIDE | experimental |
|        |                | DB08403        | METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID | experimental |
|        |                | DB08482        | [[1-N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER | experimental |
|        |                | DB08491        | N-HYDROXY-2-[4-(4-PHENOXYSULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE | experimental |
| MMP2   | P08253         | DB00786        | Marimastat | investigational |
|        |                | DB01630        | SC-74020 | experimental |
|        |                | DB04866        | Halofuginone | vet_approved |
|        |                | DB05387        | AE-941 | investigational |
|        |                | DB06423        | Endostatin | investigational |
|        |                | DB01197        | Captopril | approved |
| MMP7   | P50280         | DB00786        | Marimastat | investigational, experimental |
|        |                | DB08170        | (1R)-N,6-DIHYDROXY-7-METHOXY-2-[[4-METHOXYPHENYL]sulfonyl]-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXYLAMIDE | experimental |
|        |                | DB08489        | N4-HYDROXY-2-ISOBUTYL-N1-[9-OXO-1,8-DIAZATRICYCLO[10.6.1.013,18]NONADEC-12-(19),13,15,17-TETRAEN-10-YL]SUCONAMIDE | experimental |
|        |                | DB08493        | 5-METHYL-3-[9-OXO-1,8-DIAZATRICYCLO[10.6.1.013,18]NONADEC-12-(19),13,15,17-TETRAEN-10-YLCARBAMOYL]-HEXANAMIDE | experimental |
| MMP9   | P14780         | DB00786        | Marimastat | investigational, approved |
|        |                | DB01017        | Minocycline | approved |
|        |                | DB01296        | Glucosamine | approved |
|        |                | DB01949        | 2-Amino-N,3,3-Trimethylbutanamide | experimental |
|        |                | DB03683        | 2-[(Formyl (Hydroxy)Amino)Methyl]-4-Methylpentanoic Acid | experimental |
|        |                | DB05387        | AE-941 | investigational |
|        |                | DB05495        | PG-53074 | investigational |
|        |                | DB06423        | Endostatin | investigational |
|        |                | DB01197        | Captopril | approved |
|        |                | DB07117        | 5-[4-(PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YL)Piperazin-1-YL]PYRIMIDINE-2,4,6 (2H,3H)-TRIONE | experimental |
| MMP11  | P24347         | DB04318        | Nα-[[2S]-2-[([S]-[1S]-1-[[Benzoyloxy]carbonyl]amino)-2-phenylethyl][hydroxy]phosphoryl][methyl]-5-phenylpentanoyl-L-tryptophanamide | experimental |
| MMP12  | P39900         | DB00786        | Marimastat | investigational |
|        |                | DB02118        | CP-271485 | experimental |
|        |                | DB00551        | Acetohydroxamic acid | approved |
|        |                | DB03367        | PF-00356231 | experimental |
|        |                | DB03880        | Batimastat | approved |
|        |                | DB04405        | 2-[2-[1,3 Dioxo-1,3-Dihydro-2h-Isindol-2-Yl]Ethyl]-4-[(4'-Ethoxy-1',1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid | experimental |
|        |                | DB05387        | AE-941 | investigational |
|        |                | DB07026        | Marimastat | investigational |
|        |                | DB07446        | N-[biphenyl-4-sulfonoyl]-D-leucine | experimental |
| MMP14  | P50281         | DB00786        | Marimastat | investigational |
| MMP28  | Q9H239         | DB00786        | Marimastat | investigational |
migration, differentiation, apoptosis, angiogenesis, tissue repair, and immune response. During the progression of tumor, extracellular proteinases mediate changes in microenvironment. Moreover, degradation of ECM is an essential step in tumor metastasis and MMPs are playing vital roles in this process. MMPs have also been proved to be correlated with the invasiveness of PC cells. However, it is unclear whether MMPs can be diagnostic biomarkers for PC. The expression of MMPs and their correlation with the pathological stages of PC were explored for the first time. We found that several MMPs were significantly upregulated while 2 MMPs were down-regulated in PC tissues compared with adjacent pancreatic tissues. MMP1, MMP2, MMP7, MMP9, MMP11, MMP12, MMP14, and MMP28 were selected as the targets of our further study. The expression of MMP1, MMP7, MMP11, and MMP14 increased as PC progressed. All target MMPs with high expression showed poor prognosis. Moreover, low expression of both MMP14 and MMP28 was significantly associated with longer DFS, and high expression levels of MMP1, MMP11, MMP14, and MMP28 were significantly associated with shorter OS in PC patients. The above data suggested that these differentially expressed MMPs may play vital roles in the progression of PC. Previous studies have also showed the abnormal expression of MMP1, MMP2, MMP7, MMP8, MMP9, and MMP11 in PC tissues.

We then explored the co-expression, genetic alteration, neighbor gene interaction network analysis of selected MMPs in PC patients to provide an integrated and comprehensive analysis of the molecular characteristics of MMPs. The genetic alterations of the selected MMPs included amplification, deep deletion and mutation. The potential interaction analysis revealed a correlation between selected MMPs and cell adhesion, spreading promotion, cell migration, inflammation, oncogenesis, metastasis, and tumorigenesis and progression. These data suggested that the selected MMPs play a synergistic role in the progression of PC. We then identified the potential transcription factors of the selected differentially expressed MMPs, and we found that ETV4, STAT3, JUN, MAZ, RELA, SRF, ETS2, SP1, FOS, and NF-κB may be key transcription factors for selected MMPs. Overexpression of ETV4 promotes progression, proliferation and invasion of many cancers. STAT3 regulates glycolysis in hepatocellular carcinoma cells, associated with inhibition of epithelial-mesenchymal transition hepatocellular carcinoma, and is related to proliferation promotion and apoptosis inhibition in esophageal squamous cell carcinoma. Previous studies have also identified a role for STAT3 in the regulation of PC. JUN, MAZ, RELA, SRF, ETS2, SP1, FOS, and NF-κB were activated in many cancers including PC. Our study provided additional data on the complicated relationship among MMPs, PC, and transcription factor-related signaling pathways. Furthermore, extracellular matrix disassembly, regulation of cell motility, regulation of cell migration, cell adhesion molecule binding and extracellular or secretory components all played vital roles as expectation. Our study suggested that the selected MMPs were involved in the tumorigenesis of PC. We also focused on drugs targeting selected MMPs, which helped us to get a clear understanding of the biological function and mechanism of these drugs. DB00786 (marimastat) was found to target all differentially expressed MMPs in PC, which provides novel insights and additional support for the use of marimastat in PC patients.

Our study has some limitations and further exploration is needed. Information from blood samples has an irreparable role in exploring diagnostic tumor biomarkers. Given that we currently do not have access to high-quality blood sample information, the results of this paper need to be further validated by in vivo and in vitro experiments. In general, our study provided potential diagnostic biomarkers and therapeutic target for PC patients.

Acknowledgments

YNP would like to thank the financial support from Changhai Hospital (2019QNB01) and the China postdoctoral science foundation.

Author contributions

Conceptualization: Yiqi Du, Yanan Pang.
Data curation: Junhao Xie, Xianzhu Zhou, Rui Wang.
Formal analysis: Junhao Xie.
Funding acquisition: Yiqi Du, Yanan Pang.
Investigation: Jian Tang, Qichen Zhang.
Methodology: Jiulong Zhao.
Project administration: Junhao Xie.
Resources: Xianzhu Zhou, Rui Wang.
Software: Junhao Xie, Xianzhu Zhou.
Supervision: Jiulong Zhao.
Validation: Yiqi Du.
Visualization: Yanan Pang.
Writing – original draft: Junhao Xie, Xianzhu Zhou.
Writing – review & editing: Rui Wang, Yiqi Du, Yanan Pang.

References

[1] Jemal A, Bray F, Center M, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
[2] Siegel R, Ma J, Zou Z, et al. Cancer statistics. CA Cancer J Clin 2014;64:9–29.
[3] Gong Z, Holly EA, Bracci PM. Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am J Epidemiol 2011;174:1373–81.
[4] Abel E, Simeone DM. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology 2010;134:1421–8.
[5] McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 2016;7:418–9.
[6] Cowgill SM, Muscarella P. The genetics of pancreatic cancer. Am J Surg 2003;186:279–86.
[7] Li D, Jiao L. Molecular epidemiology of pancreatic cancer. Int J Gastrointest Cancer 2003;33:3–14.
[8] Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 2019;10:10–27.
[9] Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605–17.
[10] Qian L, Li Q, Baryeh K, et al. Biosensors for early diagnosis of pancreatic cancer: a review. Transl Res 2019;213:67–89.
[11] Chen WG, Yuan J, Xing Y, et al. An integrated analysis of heterogeneous pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim Biophys Acta 2007;1774:764–71.
[12] Scheurer U. Pancreatic carcinoma: diagnosis. Ther Umsch 1996;53:377–86.
[13] Su SB, Qin SY, Chen W, et al. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323–33.
Cheng Y, Wang K, Geng L, et al. Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma. ElBioMedicine 2019;40:382–93.

Kimbara S, Kondo S. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol 2016;22:7441–7.

Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827–39.

Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci 2017;147:1–73.

Reuter JA, Spacek DV, Snyder MP. High-throughput sequencing of human. Mol Cell 2015;58:586–97.

Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol 2016;1418:93–110.

Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1–6.

Rhodes DR, Kalyana-Sundaram S, Mahavanso V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007;9:166–80.

Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017;45:W98–102.

Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an integrated platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:404–14.

Sziklavecz D, Morris J, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 2017;45:D362–8.

Franz M, Rodriguez H, Lopes C, et al. GeneMANIA update 2018. Nucleic Acids Res 2018;46:W60–64.

Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44–57.

Wishart DS, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34:D668–72.

Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018;46: D1047–82.

Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12:56–68.

Ito T, Ito M, Shiozawa J, et al. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol 1999;12:669–74.

Li Y, Song T, Chen Z, et al. Pancreatic stellate cells activation and matrix metalloproteinase-2 expression correlate with lymph node metastasis in pancreatic carcinoma. Am J Med Sci 2019;357:16–22.

Zhai LL, Wu Y, Cai CY, et al. Upregulated matrix metalloproteinase-2 and downregulated tissue factor pathway inhibitor-2 are risk factors for lymph node metastasis and perineural invasion in pancreatic carcinoma. Onco Targets Ther 2015;8:2827–34.

Bramhall SR, Neoptolemos JP, Stamp GW, et al. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997;182:347–55.

Bourret B, Pointreau A, Souque A, et al. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. Pancreatology 2012;12:27–34.

Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004;10: 2832–43.

Gao L, Zhong JC, Huang WT, Dang YW, Kang M, Chen G. Integrative analysis of BSG expression in NPC through immunohistochemistry and public high-throughput gene expression data. Am J Transl Res 2017;9: 4574–92.

Frick VO, Rubie C, Wagner M, et al. Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases. Pancreatology 2008;8:488–97.

Rao X, Wan L, Jie Z, Zhu X, Yin J, Cao H. Upregulated miR-27a-3p indicates a poor prognosis in pancreatic carcinoma patients and promotes the angiogenesis and migration by epigenetic silencing of GATA6 and activating VEGFA/VEGFR2 signaling pathway. Onco Targets Ther 2019;12:11241–54.

Xu Y, Xiao Q, Rao Q, et al. DCN deficiency promotes renal cell carcinoma growth and metastasis through downregulation of P21 and E-cadherin. Tumour Biol 2016;37:1571–83.

Li XP, Zhang XW, Zheng LZ, et al. Expression of CD44 in pancreatic cancer and its significance. Int J Clin Exp Pathol 2015;8:6724–31.

Kim E, Kim D, Lee J-S, et al. Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis. Hepatology 2018;67:2287–301.

Zuo C, Hong Y, Qiu X, et al. Cilexobix suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3/NF-kB and IL-6/IL10 and controls tumourigenicity. Int J Cancer 2018;143:140–53.

Chen G, Shi Y, Zhang Y, Sun J. CircRNA_100782 regulates pancreatic cancer proliferation through the IL6-STAT3 pathway. Onco Targets Ther 2017;10:5738–94.

Zhu X, Luo W, Liang W, et al. Overexpression and clinical significance of MYC-associated zinc finger protein in pancreatic carcinoma. Onco Targets Ther 2016;9:493–501.

Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res 2006;12:2969–72.

Wang X, Wu X, Zhang Z, et al. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 2018;8:17914.

Ito Y, Miyoshi E, Takeda T, et al. Ets-2 overexpression contributes to progression of pancreatic adenocarcinoma. Oncol Rep 2002;9:853–7.

Maly M, Graf B, Buntzer A. The effects of analgesics and local anesthetics on gene transcription mediated by NFATc2 and Sp1 in pancreatic carcinoma. Anticancer Res 2019;39:4721–8.

Li S, Fu H, Wang Y, et al. MicroRNA-101 regulates expression of the v-fos FB1 murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology 2009;49:1194–202.

Garg B, Giri B, Modi S, et al. NF-kB in pancreatic stellate cells reduces infiltration of tumors by cytotoxic T cells and killing of cancer cells, via up-regulation of CXCL12. Gastroenterology 2018;155: 880–891.6.

Lorenz R, Aleksic T, Wagner M, Adler G, Weber CK. The cAMP/Epac1/ Rap1 pathway in pancreatic carcinoma. Pancreas 2008;37:102–3.

Zhang L, Li C, Mahmood R, et al. Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer. Cancer Res 2006; 66:898–906.

Parperis K, Constantinidou A, Panos G. Panarneoplastic arthritides: insights to pathogenesis, diagnostic approach, and treatment. J Clin Rheumatol 2019. doi: 10.1097/RHU.0000000000001202. Online ahead of print.

Zhu S, Deng S, He C, et al. Reciprocal loop of hypoxia-inducible factor-1α (HIF-1α) and metastasis-associated protein 2 (MTA2) contributes to the progression of pancreatic carcinoma by suppressing E-cadherin transcription 2018;245:349–60.

Zhu JH, Mello RA, Yan QL, et al. MiR-139-5p/SLC7A11 inhibits the proliferation, invasion and metastasis of pancreatic carcinoma via PI3K/ Akt signaling pathway. Biochim Biophys Acta Mol Basis Dis 2020;1866:165747.

Yan X, Hui Y, Hua Y, et al. EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway. Biomed Pharmacother 2019;109:762–9.

Furuyama K, Doi R, Mori T, et al. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg 2006;30:219–26.

Santos R, Ureso O, Gauston A, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov 2017;16:19–34.

Maekawa K, Sato H, Furukawa M, et al. Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral carcinoma progression model. Cancer Res 2002;62:34–80.

Kimata M, Otani Y, Kubota T, et al. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. Jpn J Cancer Res 2002;93:834–41.

Bramhall SR, Hallissy MT, Whiting J, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002;86:1864–70.

Shepherd FA, Giuseppe Giaccone G, Seymour L, et al. Prospective, randomized, double-blinded, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada- Clinical Trials
Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002;20:4434–9.

[65] Steward WP, Thomas AL. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs 2000; 9:2913–22.

[66] Saif MW. Anti-angiogenesis therapy in pancreatic carcinoma. JOP 2006;7:163–73.

[67] Rosemurgy A, Harris J, Langleben A, et al. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 1999;22:247–52.

[68] Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001;19:3447–55.

[69] Cheng T, Zhang Z, Cheng Y, et al. ETV4 promotes proliferation and invasion of lung adenocarcinoma by transcriptionally upregulating MSI2. Biochem Biophys Res Commun 2019;516:278–84.

[70] Wang Y, Ding X, Liu B, et al. ETV4 overexpression promotes progression of non-small cell lung cancer by upregulating PXN and MMP1 transcriptions. Mol Carcinog 2020;59:73–86.

[71] Li M, Jin R, Wang W, et al. STAT3 regulates glycolysis via targeting hexokinase 2 in hepatocellular carcinoma cells. Oncotarget 2017;8: 24777–84.

[72] Yang L, Zhang XY, Li K, et al. Protopanaxadiol inhibits epithelial-mesenchymal transition of hepatocellular carcinoma by targeting STAT3 pathway. Cell Death Dis 2019;10:630.

[73] Liu Y, Zhi Y, Song H, et al. S1PR1 promotes proliferation and inhibits apoptosis of esophageal squamous cell carcinoma through activating STAT3 pathway. J Exp Clin Cancer Res 2019;38:369.

[74] Amedei A, Niccolai E, Benagiano M, et al. Ex vivo analysis of pancreatic cancer-infiltrating Tlymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother 2013;62:1249–60.